Literature DB >> 8451197

IGH minisatellite suppression of USF-binding-site- and E mu-mediated transcriptional activation of the adenovirus major late promoter.

W L Trepicchio1, T G Krontiris.   

Abstract

The 50bp repeat unit of the minisatellite within the DH-JH interval of the human immunoglobulin heavy chain locus binds a nuclear factor present in a wide variety of cell types. The binding site contains the myc/HLH motif, CACGTG, and represents a 15 of 17 base match for the USF/MLTF binding site adjacent to the adenovirus major late promoter (MLP). Unlike the USF/MLTF site, the IGH minisatellite possesses no enhancer activity. However, it can significantly suppress, in cis and in trans, USF-site-mediated transcriptional activation of the MLP. In murine myeloma cells, the IGH minisatellite can suppress, in trans, MLP activation by the murine heavy chain gene enhancer, E mu. These activities potentially represent a DNA-based form of squelching.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8451197      PMCID: PMC309232          DOI: 10.1093/nar/21.4.977

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  15 in total

1.  The leucine zipper of TFE3 dictates helix-loop-helix dimerization specificity.

Authors:  H Beckmann; T Kadesch
Journal:  Genes Dev       Date:  1991-06       Impact factor: 11.361

2.  Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity.

Authors:  Y F Hu; B Lüscher; A Admon; N Mermod; R Tjian
Journal:  Genes Dev       Date:  1990-10       Impact factor: 11.361

3.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

4.  In vivo functional analysis of in vitro protein binding sites in the immunoglobulin heavy chain enhancer.

Authors:  B P Tsao; X F Wang; C L Peterson; K Calame
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

5.  The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Authors:  D W Ballard; W H Walker; S Doerre; P Sista; J A Molitor; E P Dixon; N J Peffer; M Hannink; W C Greene
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

6.  Immunoglobulin heavy-chain enhancer requires one or more tissue-specific factors.

Authors:  M Mercola; J Goverman; C Mirell; K Calame
Journal:  Science       Date:  1985-01-18       Impact factor: 47.728

7.  A dominant negative form of transcription activator mTFE3 created by differential splicing.

Authors:  C Roman; L Cohn; K Calame
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

8.  Stimulation of in vitro transcription by the upstream element of the adenovirus-2 major late promoter involves a specific factor.

Authors:  N G Miyamoto; V Moncollin; M Wintzerith; R Hen; J M Egly; P Chambon
Journal:  Nucleic Acids Res       Date:  1984-12-11       Impact factor: 16.971

9.  Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro.

Authors:  N Mermod; T J Williams; R Tjian
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

10.  NF-kappa B contacts DNA by a heterodimer of the p50 and p65 subunit.

Authors:  M B Urban; R Schreck; P A Baeuerle
Journal:  EMBO J       Date:  1991-07       Impact factor: 11.598

View more
  3 in total

1.  Maximal stimulation of meiotic recombination by a yeast transcription factor requires the transcription activation domain and a DNA-binding domain.

Authors:  D T Kirkpatrick; Q Fan; T D Petes
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

Review 2.  Mini- and microsatellites.

Authors:  C Ramel
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

3.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.

Authors:  N Siegelmann-Danieli; K H Buetow
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.